Table 1.
FDA-approved, CAR T-mediated therapies for hematological cancer
| S No | Trade Names | Proper Names | Route of administration | Indicated diseases | Years of approval |
|---|---|---|---|---|---|
| 1 | KYMRIAH | Tisagenlecleucel | Intravenous infusion | Lymphoma | 2017 |
| 2 | YESCARTA | Axicabtagene ciloleucel | Intravenous infusion | Lymphoma | 2017 |
| 3 | TECARTUS | Brexucabtagene autoleucel | Intravenous infusion | Lymphoma, acute lymphoblastic leukemia | 2020 |
| 4 | ABECMA | Idecabtagene vicleucel | Intravenous infusion | Multiple myeloma | 2021 |
| 5 | BREYANZI | Lisocabtagene maraleucel | Intravenous infusion | B cell lymphoma, follicular lymphoma | 2021 |
| 6 | CARVYKTI | Ciltacabtagene autoleucel | Intravenous infusion | Multiple myeloma | 2022 |